Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C11H15N2O3.Na |
| Molecular Weight | 246.2382 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CC(C)C1(CC=C)C(=O)[N-]C(=O)N(C)C1=O
InChI
InChIKey=FWUAYRKNHAUSPM-UHFFFAOYSA-M
InChI=1S/C11H16N2O3.Na/c1-5-6-11(7(2)3)8(14)12-10(16)13(4)9(11)15;/h5,7H,1,6H2,2-4H3,(H,12,14,16);/q;+1/p-1
| Molecular Formula | C11H16N2O3 |
| Molecular Weight | 224.2563 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | Na |
| Molecular Weight | 22.9898 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The stereoselective effects of bucolome on the pharmacokinetics and pharmacodynamics of racemic warfarin. | 2001 Apr |
|
| Metabolism of bucolome in rats. Stability and biliary excretion of bucolome N-glucuronide. | 2001 Aug 5 |
|
| Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome. | 2005 Apr |
|
| Usefulness of coadministration of bucolome in warfarin therapy: pharmacokinetic and pharmacodynamic analysis using outpatient prescriptions. | 2005 Apr 11 |
|
| [Intraluminal ureteral hematoma complicating anticoagulant therapy]. | 2005 Jul |
|
| The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan. | 2008 |
|
| Influences of haemodialysis on the binding sites of human serum albumin: possibility of an efficacious administration plan using binding inhibition. | 2008 Jul |
|
| Interferon-alpha is a predisposing risk factor for carbamazepine-induced hyponatremia: A case of syndrome of inappropriate antidiuresis caused by interferon-alpha therapy. | 2008 Nov 30 |
|
| Risks and benefits of combined use of bucolome and warfarin in anticoagulation therapy. | 2010 |
|
| Hydrogen-bond motifs in N-monosubstituted derivatives of barbituric acid: 5-allyl-5-isopropyl-1-methylbarbituric acid (enallylpropymal) and 1,5-di(but-2-enyl)-5-ethylbarbituric acid. | 2010 Jan |
|
| Identification of the UDP-glucuronosyltransferase responsible for bucolome N-glucuronide formation in rats. | 2010 Nov |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:32:21 UTC 2023
by
admin
on
Sat Dec 16 09:32:21 UTC 2023
|
| Record UNII |
2N3C21X38F
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
59005-68-4
Created by
admin on Sat Dec 16 09:32:21 UTC 2023 , Edited by admin on Sat Dec 16 09:32:21 UTC 2023
|
PRIMARY | |||
|
m716
Created by
admin on Sat Dec 16 09:32:21 UTC 2023 , Edited by admin on Sat Dec 16 09:32:21 UTC 2023
|
PRIMARY | Merck Index | ||
|
91667971
Created by
admin on Sat Dec 16 09:32:21 UTC 2023 , Edited by admin on Sat Dec 16 09:32:21 UTC 2023
|
PRIMARY | |||
|
2N3C21X38F
Created by
admin on Sat Dec 16 09:32:21 UTC 2023 , Edited by admin on Sat Dec 16 09:32:21 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
